Myostatin: a Circulating Biomarker Correlating with Disease in Myotubular Myopathy Mice and Patients
暂无分享,去创建一个
Arturo E. Hernandez | L. Servais | A. D’Amico | N. Voermans | J. Laporte | C. Kretz | J. Cuisset | U. Schara | J. Baets | C. Vuillerot | L. Thielemans | M. Mayer | J. Arnal | S. Buono | B. Cowling | C. Koch | M. Annoussamy | Arturo Hernández | C. de Lattre | S. Fontaine | A. Robé | A. Seferian | A. Monseur | R. Bellance | Raquel Gómez-Oca | M. Depla | A. Béhin | A. Menuet | S. Djeddi | Mélanie Andreea Jonathan Nicole Antony U. Adele Arturo Cap Annoussamy Seferian Baets Voermans Behin | Michèle Mayer | Jonathan Baets | Nicole Voermans | Antony Behin | U. Schara | Adele D’Amico | Jean-Michel Arnal | Carole Vuillerot | Rémy Bellance
[1] R. Grange,et al. AAV-Mediated Gene Transfer Restores a Normal Muscle Transcriptome in a Canine Model of X-Linked Myotubular Myopathy. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.
[2] L. Thielemans,et al. Translational medicine in neuromuscular disorders: from academia to industry , 2019, Disease Models & Mechanisms.
[3] Jin-hai Tang,et al. MiR-27a: A Novel Biomarker and Potential Therapeutic Target in Tumors , 2019, Journal of Cancer.
[4] L. Servais,et al. X-linked myotubular myopathy , 2019, Neurology.
[5] Arun K. Ramani,et al. Tamoxifen therapy in a murine model of myotubular myopathy , 2018, Nature Communications.
[6] Shuling Guo,et al. Reducing dynamin 2 (DNM2) rescues DNM2-related dominant centronuclear myopathy , 2018, Proceedings of the National Academy of Sciences.
[7] L. Servais,et al. An integrated modelling methodology for estimating the prevalence of centronuclear myopathy , 2018, Neuromuscular Disorders.
[8] N. Messaddeq,et al. Single Intramuscular Injection of AAV-shRNA Reduces DNM2 and Prevents Myotubular Myopathy in Mice. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] A. Roux,et al. Amphiphysin (BIN1) negatively regulates dynamin 2 for normal muscle maturation , 2017, The Journal of clinical investigation.
[10] F. Muntoni,et al. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches , 2017, Nature Communications.
[11] Shuling Guo,et al. Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice , 2017, Nature Communications.
[12] Hanns Lochmüller,et al. Reduced serum myostatin concentrations associated with genetic muscle disease progression , 2017, Journal of Neurology.
[13] F. Muntoni,et al. Cellular, biochemical and molecular changes in muscles from patients with X-linked myotubular myopathy due to MTM1 mutations , 2016, Human molecular genetics.
[14] Richard T. Lee,et al. Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation. , 2016, Circulation research.
[15] A. Gomes,et al. Acute resistance exercise activates rapamycin‐sensitive and ‐insensitive mechanisms that control translational activity and capacity in skeletal muscle , 2016, The Journal of physiology.
[16] I. Clay,et al. GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration. , 2015, Cell metabolism.
[17] G. Ravenscroft,et al. Pathophysiological concepts in the congenital myopathies: blurring the boundaries, sharpening the focus. , 2015, Brain : a journal of neurology.
[18] Shelly C. Lu,et al. Activation of a novel c-Myc-miR27-prohibitin 1 circuitry in cholestatic liver injury inhibits glutathione synthesis in mice. , 2015, Antioxidants & redox signaling.
[19] E. Malfatti,et al. Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations. , 2014, Brain : a journal of neurology.
[20] Fujun Liu,et al. Differential muscle hypertrophy is associated with satellite cell numbers and Akt pathway activation following activin type IIB receptor inhibition in Mtm1 p.R69C mice. , 2014, The American journal of pathology.
[21] N. Romero,et al. Reducing dynamin 2 expression rescues X-linked centronuclear myopathy. , 2014, The Journal of clinical investigation.
[22] Jocelyn Laporte,et al. Mutation spectrum in the large GTPase dynamin 2, and genotype–phenotype correlation in autosomal dominant centronuclear myopathy , 2012, Human mutation.
[23] E. Olson,et al. Mice lacking microRNA 133a develop dynamin 2–dependent centronuclear myopathy. , 2011, The Journal of clinical investigation.
[24] I. Nishino,et al. Molecular Pathogenesis of Genetic and Inherited Diseases Increased Expression of Wild-Type or a Centronuclear Myopathy Mutant of Dynamin 2 in Skeletal Muscle of Adult Mice Leads to Structural Defects and Muscle Weakness , 2011 .
[25] A. Buj-Bello,et al. Molecular Pathogenesis of Genetic and Inherited Diseases Inhibition of Activin Receptor Type IIB Increases Strength and Lifespan in Myotubularin-Deficient Mice , 2011 .
[26] J. Lainé,et al. A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice. , 2010, Human molecular genetics.
[27] Andrea M. Hanson,et al. CCAAT/enhancer binding protein-delta expression is increased in fast skeletal muscle by food deprivation and regulates myostatin transcription in vitro. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.
[28] J. Reecy,et al. Myostatin genotype regulates muscle-specific miRNA expression in mouse pectoralis muscle , 2010, BMC Research Notes.
[29] Straub,et al. RYR1 mutations are a common cause of congenital myopathies with central nuclei , 2010, Annals of neurology.
[30] A. Siwkowski,et al. Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogs. , 2008, Nucleic acids symposium series.
[31] A. Goldberg,et al. Identification of a Novel Pool of Extracellular Pro-myostatin in Skeletal Muscle* , 2008, Journal of Biological Chemistry.
[32] C. Wallgren‐Pettersson,et al. Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy , 2007, Nature Genetics.
[33] A. Beggs,et al. Mutations in dynamin 2 cause dominant centronuclear myopathy , 2005, Nature Genetics.
[34] V. Ambros,et al. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation , 2004, Genome Biology.
[35] Hala G. Zahreddine,et al. The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[36] Se-Jin Lee,et al. Regulation of myostatin activity and muscle growth , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[37] Se-Jin Lee,et al. Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member , 1997, nature.
[38] S. Klauck,et al. A gene mutated in X–linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast , 1996, Nature Genetics.
[39] D. Allen,et al. Posttranscriptional mechanisms involving microRNA-27a and b contribute to fast-specific and glucocorticoid-mediated myostatin expression in skeletal muscle. , 2011, American journal of physiology. Cell physiology.
[40] A. Nakamura,et al. MicroRNA-206 is highly expressed in newly formed muscle fibers: implications regarding potential for muscle regeneration and maturation in muscular dystrophy. , 2008, Cell structure and function.